TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of gynecologic cancers.

PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this CNE (NCPD) activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with gynecologic cancers.

LEARNING OBJECTIVES

• Consider the FDA approvals of olaparib and niraparib as maintenance therapy after first-line platinum-based chemotherapy for advanced ovarian cancer (OC), and counsel patients with and without BRCA mutations regarding appropriate treatment recommendations.
• Recall the FDA approval of olaparib/bevacizumab as maintenance therapy for patients with newly diagnosed advanced OC responding after first-line platinum-based chemotherapy with bevacizumab whose disease is homologous recombination deficiency-positive to assess the role of this novel strategy in clinical practice.
• Appreciate the biologic rationale for and available data with the use of veliparib in combination with chemotherapy, and consider the clinical and research implications for the management of OC.
• Understand the importance of microsatellite instability (MSI) testing for patients with gynecologic cancers, and identify the benefits observed with anti-PD-1/PD-L1 antibodies for MSI-high or mismatch repair-deficient disease.
• Recognize the FDA approval of pembrolizumab in combination with lenvatinib for advanced, recurrent endometrial cancer that is not MSI high or mismatch repair deficient to identify patients appropriate for this novel approach.
• Evaluate the efficacy and safety of anti-PD-1 monotherapy for PD-L1-positive recurrent or metastatic cervical cancer that progresses on or after chemotherapy, and use this information to educate patients about the benefits and risks associated with this approach.
• Assess the toxicities associated with PARP inhibitors and immune checkpoint inhibitors used for gynecologic cancers, and offer patients supportive management strategies to minimize and ameliorate these side effects.

ACCREDITATION STATEMENT
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

CREDIT DESIGNATION STATEMENTS
CME credit is no longer available for this issue

ONCC/ILNA CERTIFICATION INFORMATION
CME credit is no longer available for this issue

FOR SUCCESSFUL COMPLETION

CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE (NCPD) activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Paula J Anastasia, RN, MN, AOCN
Gyn-Oncology Clinical Nurse Specialist
UCLA Medical Center
David Geffen School of Medicine
Los Angeles, California

No financial interests or affiliations to disclose.

Jennifer Filipi, MSN, NP
Massachusetts General Hospital
Center for Gynecologic Oncology
Boston, Massachusetts

No financial interests or affiliations to disclose.

David M O’Malley, MD
Professor
Division Director, Gynecologic Oncology
Co-Director, Gynecologic Oncology Phase I Program
The Ohio State University and The James Cancer Center
Columbus, Ohio

Advisory Committee: AbbVie Inc, Agenus Inc, Ambry Genetics, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genelux, Genentech, a member of the Roche Group, GOG Foundation Inc, ImmunoGen Inc, Janssen Biotech Inc, Leap Therapeutics Inc, Merck, Myriad Genetic Laboratories Inc, Novocure, Regeneron Pharmaceuticals Inc, Tarveda Therapeutics, Tesaro, A GSK Company; Consulting Agreements: AbbVie Inc, Agenus Inc, Ambry Genetics, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Genmab, GOG Foundation Inc, ImmunoGen Inc, Novocure, Regeneron Pharmaceuticals Inc, Seattle Genetics, Tesaro, A GSK Company; Contracted Research: AbbVie Inc, Agenus Inc, Ajinomoto Co Inc, Amgen Inc, Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Clovis Oncology, Daré Bioscience, Eisai Inc, EMD Serono Inc, Ergomed Plc, Genentech, a member of the Roche Group, Genmab, GlaxoSmithKline, GOG Foundation Inc, ImmunoGen Inc, Iovance Biotherapeutics Inc, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Ludwig Institute for Cancer Research Ltd, Merck, New Mexico Cancer Care Alliance, Novocure, PRA Health Sciences, Regeneron Pharmaceuticals Inc, Seattle Genetics, Stemcentrx, Syneos Health, Tesaro, A GSK Company, TRACON Pharmaceuticals Inc, VentiRx Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: Marker Therapeutics Inc.

Shannon N Westin, MD, MPH
Associate Professor
Director, Early Drug Development
Department of Gynecologic Oncology and Reproductive Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Consulting Agreements: AstraZeneca Pharmaceuticals LP, Circulogene, Clovis Oncology, Genentech, a member of the Roche Group, Merck, Novartis, Pfizer Inc, Tesaro, A GSK Company; Contracted Research: ArQule Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Cotinga Pharmaceuticals, Genentech, a member of the Roche Group, Novartis, Tesaro, A GSK Company; Data and Safety Monitoring Board/Committee: Xenetic Biosciences.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.

RTP CNE (NCPD) PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc and Merck.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
Adobe Flash Player 27 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Audio Release date: September 2020
Audio Expiration date: September 2021

Video Release date: July 2020
Video Expiration date: July 2021

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.